September 07, 2018
A New Jersey federal judge on Friday overrode a jury's verdict and instead found that EMD Serono Inc. and Pfizer Inc. infringed Biogen MA Inc.'s valid patent for the multiple sclerosis treatment Avonex.
April 26, 2018
A New Jersey federal jury rightly found that a Biogen MA Inc. patent covering its multiple sclerosis treatment Avonex was invalid, because while the patent covered a new process, the treatment was decades old, EMD Serono Inc. told the court Wednesday.
March 26, 2018
Biogen MA Inc. on Friday asked a New Jersey federal judge to override a jury's verdict finding claims in a patent covering the multiple sclerosis treatment Avonex invalid or to redo the trial accusing EMD Serono Inc. and Pfizer Inc. of infringing that patent.
February 26, 2018
After a nearly eight-year legal battle, a New Jersey federal jury Friday handed down a verdict for EMD Serono and Pfizer in a lawsuit in which Biogen asserted that the sale of Rebif, Serono's multiple sclerosis treatment co-promoted by Pfizer, infringed Biogen's patent related to its own drug Avonex.